Skip to main content


Below you'll find a list of recent publications from the Sonabend Lab and its collaborators. For a more comprehensive list, please visit Sonabend's PubMed listing.

  1. Fares J, Petrosyan E, Kanojia D, Dmello C, Cordero A, Duffy JT, Yeeravalli R, Sahani MH, Zhang P, Rashidi A  et al.  Metixene is an incomplete autophagy inducer in preclinical models of metastatic cancer and brain metastases.  J Clin Invest  2023 Oct 17;. pii:e161142
  2. Nandoliya KR, Khazanchi R, Winterhalter EJ, Youngblood MW, Karras CL, Sonabend AM, Micco AG, Chandler JP, Magill ST  Validating the VS-5 Score for Predicting Outcomes After Vestibular Schwannoma Resection in an Institutional Cohort.  World Neurosurg  2023 Aug;176:e77-e82. doi:10.1016/j.wneu.2023.04.123
  3. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H  et al.  Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.  Nat Med  2023 Jun;29(6):1370-1378. doi:10.1038/s41591-023-02347-y
  4. Gould A, Gonzales VAA, Dmello CC, Saganty R, Lukas RV, Zhang DY, Heimberger AB, Canney M, Carpentier A, Desseaux C  et al.  Advances in Blood-Brain Barrier Disruption to Facilitate Drug Delivery for Infiltrative Gliomas.  Adv Oncol  2023 May;3(1):77-86. doi:10.1016/j.yao.2023.01.017
  5. Sonabend AM, Gould A, Amidei C, Ward R, Schmidt KA, Zhang DY, Gomez C, Bebawy JF, Liu BP, Bouchoux G  et al.  Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial.  Lancet Oncol  2023 May;24(5):509-522. doi:10.1016/S1470-2045(23)00112-2
  6. Sachdev S, Dmello C, Sonabend AM  Radiosensitization of IDH-Mutated Gliomas through ZMYND8 - a Pathway to Improved Outcomes.  Clin Cancer Res  2023 May 01;29(9):1648-1650. doi:10.1158/1078-0432.CCR-23-0018
  7. Petrosyan E, Fares J, Fernandez LG, Yeeravalli R, Dmello C, Duffy JT, Zhang P, Lee-Chang C, Miska J, Ahmed AU  et al.  Endoplasmic Reticulum Stress in the Brain Tumor Immune Microenvironment.  Mol Cancer Res  2023 May 01;21(5):389-396. doi:10.1158/1541-7786.MCR-22-0920
  8. Zhang P, Rashidi A, Zhao J, Silvers C, Wang H, Castro B, Ellingwood A, Han Y, Lopez-Rosas A, Zannikou M  et al.  STING agonist-loaded, CD47/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma.  Nat Commun  2023 Mar 23;14(1):1610. pii:1610
  9. Dmello C, Zhao J, Chen L, Gould A, Castro B, Arrieta VA, Zhang DY, Kim KS, Kanojia D, Zhang P  et al.  Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade.  Nat Commun  2023 Mar 22;14(1):1566. pii:1566
  10. Zannikou M, Duffy JT, Levine RN, Seblani M, Liu Q, Presser A, Arrieta VA, Chen CJ, Sonabend AM, Horbinski CM  et al.  IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.  J Immunother Cancer  2023 Feb;11(2). pii:e006239
  11. Arrieta VA, Dmello C, McGrail DJ, Brat DJ, Lee-Chang C, Heimberger AB, Chand D, Stupp R, Sonabend AM  Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.  J Clin Invest  2023 Jan 17;133(2). pii:e163447
  12. Sita TL, Gopalakrishnan M, Rooney MK, Ho A, Savoor R, Sonabend AM, Tate MC, Chandler JP, Lesniak MS, Kruser TJ  et al.  Mean Brain Dose Remains Uninfluenced by the Lesion Number for Gamma Knife Stereotactic Radiosurgery for 10+ Metastases.  World Neurosurg  2022 Sep;165:e380-e385. doi:10.1016/j.wneu.2022.06.057
  13. Cao TQ, Wainwright DA, Lee-Chang C, Miska J, Sonabend AM, Heimberger AB, Lukas RV  Next Steps for Immunotherapy in Glioblastoma.  Cancers (Basel)  2022 Aug 20;14(16). pii:4023
  14. Dmello C, Sonabend A, Arrieta VA, Zhang DY, Kanojia D, Chen L, Gould A, Zhang J, Kang SJ, Winter J  et al.  Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.  Clin Cancer Res  2022 Jul 15;28(14):3156-3169. doi:10.1158/1078-0432.CCR-21-2563
  15. Larkin CJ, Arrieta VA, Najem H, Li G, Zhang P, Miska J, Chen P, James CD, Sonabend AM, Heimberger AB  Myeloid Cell Classification and Therapeutic Opportunities Within the Glioblastoma Tumor Microenvironment in the Single Cell-Omics Era.  Front Immunol  2022;13:907605. pii:907605
  16. Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A  et al.  Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression.  JCI Insight  2022 May 09;7(9). pii:e157612
  17. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2022 Mar;3(3):373. doi:10.1038/s43018-022-00343-8
  18. Arrieta VA, Najem H, Petrosyan E, Lee-Chang C, Chen P, Sonabend AM, Heimberger AB  The Eclectic Nature of Glioma-Infiltrating Macrophages and Microglia.  Int J Mol Sci  2021 Dec 13;22(24). pii:13382
  19. Gould A, Zhang D, Arrieta VA, Stupp R, Sonabend AM  Delivering albumin-bound paclitaxel across the blood-brain barrier for gliomas.  Oncotarget  2021 Dec 07;12(25):2474-2475. doi:10.18632/oncotarget.28018
  20. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C  et al.  ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.  Nat Cancer  2021 Dec;2(12):1372-1386. doi:10.1038/s43018-021-00260-2
  21. Zhang DY, Gould A, Happ HC, Youngblood MW, Dmello C, Kang SJ, Canney M, Stupp R, Carvill GL, Sonabend AM  Ultrasound-mediated blood-brain barrier opening increases cell-free DNA in a time-dependent manner.  Neurooncol Adv  2021;3(1):vdab165. pii:vdab165
  22. Gonzalez-Buendia E, Zhao J, Wang L, Mukherjee S, Zhang D, Arrieta VA, Feldstein E, Kane JR, Kang SJ, Lee-Chang C  et al.  TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.  Clin Cancer Res  2021 Oct 15;27(20):5669-5680. doi:10.1158/1078-0432.CCR-21-0312
  23. Fares J, Ahmed AU, Ulasov IV, Sonabend AM, Miska J, Lee-Chang C, Balyasnikova IV, Chandler JP, Portnow J, Tate MC  et al.  Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.  Lancet Oncol  2021 Aug;22(8):1103-1114. doi:10.1016/S1470-2045(21)00245-X
  24. Moreno-Jiménez S, Alegría-Loyola MA, Sonabend AM, Romano SK, Romo CG  Management of glioblastoma: a perspective from Mexico.  Chin Clin Oncol  2021 Aug;10(4):44. doi:10.21037/cco-20-129
  25. Zhang DY, Singer L, Sonabend AM, Lukas RV  Gene Therapy for the Treatment of Malignant Glioma.  Adv Oncol  2021 May;1:189-202. doi:10.1016/j.yao.2021.02.016
  26. Chastkofsky MI, Pituch KC, Katagi H, Zannikou M, Ilut L, Xiao T, Han Y, Sonabend AM, Curiel DT, Bonner ER  et al.  Mesenchymal Stem Cells Successfully Deliver Oncolytic Virotherapy to Diffuse Intrinsic Pontine Glioma.  Clin Cancer Res  2021 Mar 15;27(6):1766-1777. doi:10.1158/1078-0432.CCR-20-1499
  27. Kumthekar P, Ko CH, Paunesku T, Dixit K, Sonabend AM, Bloch O, Tate M, Schwartz M, Zuckerman L, Lezon R  et al.  A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastoma.  Sci Transl Med  2021 Mar 10;13(584). pii:eabb3945
  28. Sonabend AM, Stupp R, Lee-Chang C, Okada H  Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy.  Oncotarget  2021 Jan 05;12(1):8-9. doi:10.18632/oncotarget.27865
  29. Lee-Chang C, Miska J, Hou D, Rashidi A, Zhang P, Burga RA, Jusué-Torres I, Xiao T, Arrieta VA, Zhang DY  et al.  Activation of 4-1BBL+ B cells with CD40 agonism and IFNγ elicits potent immunity against glioblastoma.  J Exp Med  2021 Jan 04;218(1). pii:e20200913
  30. Youngblood MW, Stupp R, Sonabend AM  Role of Resection in Glioblastoma Management.  Neurosurg Clin N Am  2021 Jan;32(1):9-22. doi:10.1016/
  31. Kinslow CJ, Rae AI, Neugut AI, Adams CM, Cheng SK, Sheth SA, McKhann GM, Sisti MB, Bruce JN, Iwamoto FM  et al.  Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma.  Br J Neurosurg  2020 Dec;34(6):690-696. doi:10.1080/02688697.2019.1710820
  32. Kam KL, Brooker SM, Mao Q, Barnea Slonim L, Yaseen NR, Brat DJ, Sonabend AM, Lukas RV  Newly diagnosed enhancing lesions: Steroid initiation may impede diagnosis of lymphoma involving the central nervous system.  J Clin Neurosci  2020 Nov;81:61-64. doi:10.1016/j.jocn.2020.09.014
  33. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM  Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy.  Neuro Oncol  2020 Oct 14;22(10):1425-1438. doi:10.1093/neuonc/noaa154
  34. Rao G, Latha K, Ott M, Sabbagh A, Marisetty A, Ling X, Zamler D, Doucette TA, Yang Y, Kong LY  et al.  Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells.  Clin Cancer Res  2020 Sep 01;26(17):4699-4712. doi:10.1158/1078-0432.CCR-19-4110
  35. Kane JR, Zhao J, Tsujiuchi T, Laffleur B, Arrieta VA, Mahajan A, Rao G, Mela A, Dmello C, Chen L  et al.  CD8+ T-cell-Mediated Immunoediting Influences Genomic Evolution and Immune Evasion in Murine Gliomas.  Clin Cancer Res  2020 Aug 15;26(16):4390-4401. doi:10.1158/1078-0432.CCR-19-3104
  36. Awah CU, Chen L, Bansal M, Mahajan A, Winter J, Lad M, Warnke L, Gonzalez-Buendia E, Park C, Zhang D  et al.  Ribosomal protein S11 influences glioma response to TOP2 poisons.  Oncogene  2020 Jul;39(27):5068-5081. doi:10.1038/s41388-020-1342-0
  37. Garton ALA, Kinslow CJ, Rae AI, Mehta A, Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce JN  et al.  Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas.  J Neurosurg  2020 May 08;134(5):1357-1367. doi:10.3171/2020.2.JNS192767
  38. Zhang DY, Dmello C, Chen L, Arrieta VA, Gonzalez-Buendia E, Kane JR, Magnusson LP, Baran A, James CD, Horbinski C  et al.  Ultrasound-mediated Delivery of Paclitaxel for Glioma: A Comparative Study of Distribution, Toxicity, and Efficacy of Albumin-bound Versus Cremophor Formulations.  Clin Cancer Res  2020 Jan 15;26(2):477-486. doi:10.1158/1078-0432.CCR-19-2182
  39. Shah PV, Arrieta VA, Lee-Chang C, Sonabend AM  Cancer Immunoediting in Gliomas: Recent Advances and Implications for Immunotherapy.  J Cell Immunol  2020;2(6):352-358. doi:10.33696/immunology.2.066
  40. Rooney MK, Golden DW, Byun J, Lukas RV, Sonabend AM, Lesniak MS, Sachdev S  Evaluation of patient education materials for stereotactic radiosurgery from high-performing neurosurgery hospitals and professional societies.  Neurooncol Pract  2020 Jan;7(1):59-67. doi:10.1093/nop/npz031
  41. Arrieta VA, Iwamoto F, Lukas RV, Sachdev S, Rabadan R, Sonabend AM  Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?  J Neurosurg  2019 Dec 06;132(5):1667-1672. doi:10.3171/2019.9.JNS192523
  42. Lukas RV, Wainwright DA, Horbinski CM, Iwamoto FM, Sonabend AM  Immunotherapy Against Gliomas: is the Breakthrough Near?  Drugs  2019 Nov;79(17):1839-1848. doi:10.1007/s40265-019-01203-z
  43. Kinslow CJ, Garton ALA, Rae AI, Marcus LP, Adams CM, McKhann GM, Sisti MB, Connolly ES, Bruce JN, Neugut AI  et al.  Extent of resection and survival for oligodendroglioma: a U.S. population-based study.  J Neurooncol  2019 Sep;144(3):591-601. doi:10.1007/s11060-019-03261-5
  44. D'Amico RS, Neira JA, Yun J, Alexiades NG, Banu M, Englander ZK, Kennedy BC, Ung TH, Rothrock RJ, Romanov A  et al.  Validation of an effective implantable pump-infusion system for chronic convection-enhanced delivery of intracerebral topotecan in a large animal model.  J Neurosurg  2019 Aug 02;:1-10. doi:10.3171/2019.3.JNS1963
  45. Sonabend AM, Stupp R  Overcoming the Blood-Brain Barrier with an Implantable Ultrasound Device.  Clin Cancer Res  2019 Jul 01;25(13):3750-3752. doi:10.1158/1078-0432.CCR-19-0932
  46. Boyett D, Kinslow CJ, Bruce SS, Sonabend AM, Rae AI, McKhann GM, Sisti MB, Bruce JN, Cheng SK, Wang TJC  Spinal location is prognostic of survival for solitary-fibrous tumor/hemangiopericytoma of the central nervous system.  J Neurooncol  2019 Jul;143(3):457-464. doi:10.1007/s11060-019-03177-0
  47. Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A  et al.  Author Correction: Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.  Nat Med  2019 Jun;25(6):1022. doi:10.1038/s41591-019-0449-8
  48. Rae AI, Mehta A, Cloney M, Kinslow CJ, Wang TJC, Bhagat G, Canoll PD, Zanazzi GJ, Sisti MB, Sheth SA  et al.  Craniotomy and Survival for Primary Central Nervous System Lymphoma.  Neurosurgery  2019 Apr 01;84(4):935-944. doi:10.1093/neuros/nyy096
  49. Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R  Newly Diagnosed Glioblastoma: A Review on Clinical Management.  Oncology (Williston Park)  2019 Mar 13;33(3):91-100. pii:623491
  50. Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T, Bordbar D, Shan D, Samanamud J, Mahajan A  et al.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.  Nat Med  2019 Mar;25(3):462-469. doi:10.1038/s41591-019-0349-y